Eli Lilly and Company reported remarkable financial results for the fourth quarter of 2024, with a revenue of $13.53 billion, marking a strong 45% increase from the prior year. This surge was primarily driven by the impressive performance of its recently launched products Mounjaro and Zepbound, which collectively contributed over $3.1 billion. Net income soared to $4.41 billion, a staggering year-over-year increase of 101.39%, translating to an earnings per share (EPS) of $4.88. The company also showcased its commitment to innovation with the initiation of several new Phase III studies and strategic investments in its manufacturing capabilities. Management remains optimistic about 2025, projecting revenues of $58 to $61 billion, driven by sustained growth in the incretin class and expanding access to their innovative therapies.